Article

Gait Speed Below 0.6 m/sec Proposed as Vital Sign

Because it is an indicator of general health and a red flag for certain conditions, gait speed alone is proposed as a vital sign.

Cummings SR, Studenski S, Ferrucci L. A Diagnosis of Dismobility-Giving Mobility Clinical Visibility. A Mobility Working Group Recommendation. JAMA (2014) Published online April 24, 2014. doi:10.1001/jama.2014.3033

Simple gait speed should be used as a vital sign for the care of older patients, these authors propose.

A diagnosis of dismobility would be defined as a very slow gait speed of ≤0.6 meters per second. Below this level, disability and poor health increase rapidly. By this definition, the prevalence of dismobility at age 60-64 is 3.1% for men and 2.7% for women, and it increases sharply at older ages.

Slow gait is a predictor of all-cause mortality. It limits independence, decreases quality of life, and is associated with increased risk of disability, hospitalization, placement in long-term care, and progression of many chronic diseases.

Measuring gait speed is simple, quick, reproducible, inexpensive, and feasible in clinical settings, say these authors, suggesting a timed 4-meter walk. Patients with slow gait speeds should be assessed for treatable conditions such as peripheral vascular disease, vitamin D deficiency, and low testosterone levels, they suggest, and counseled about a program of regular exercise and physical therapy.

Dismobility is distinct from other measurements of poor mobility, because it is based on gait speed only. The Short Physical Performance Battery (SPPB), for example, also includes static balance and timed chair rises.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.